Dopaminergic agonist Ro 8-4650 in Parkinson's disease
- 29 January 2009
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 58 (1) , 74-76
- https://doi.org/10.1111/j.1600-0404.1978.tb02862.x
Abstract
An isoquinoline derivative Ro 8-4650 (dl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride) with dopaminergic properties was studied in a randomized crossover trial. The group studied comprised 37 patients with idiopathic parkinsonism and persistent symptoms, despite levodopa treatment. Median Webster rating before allocation was 11.5. The trial drug did not differ significantly from placebo as regards effect and involuntary movements. It led to more frequent minor side-effects.This publication has 4 references indexed in Scilit:
- PARKINSON'S DISEASE TREATED WITH SINEMET OR MADOPARActa Neurologica Scandinavica, 1976
- Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's diseaseZeitschrift für Neurologie, 1975
- The Two-Period Change-Over Design and Its Use in Clinical TrialsPublished by JSTOR ,1965